Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018
June 2018
982
About the Report
About the Report
Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018
Summary
GlobalData's clinical trial report, Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Products
Products
Renal Cell Carcinoma Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Renal Cell Carcinoma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Pfizer Inc
Novartis AG
Bayer AG
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Merck & Co Inc
AstraZeneca Plc
Amgen Inc
Eisai Co Ltd
Table of Contents
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Renal Cell Carcinoma Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Renal Cell Carcinoma 31
Jun 20, 2018: SillaJen enrols first patient in REN026 trial 31
Jun 13, 2018: TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer 31
Jun 12, 2018: Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 31
Jun 11, 2018: Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations 32
Jun 03, 2018: Merck's KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study 32
Jun 03, 2018: Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) Combination Therapy in Four Different Tumor Types 33
Jun 03, 2018: Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery 35
Jun 01, 2018: Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study 35
May 17, 2018: Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting 36
May 16, 2018: New Data from Merck's Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting 37
May 08, 2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo (nivolumab) 38
May 04, 2018: CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia 38
Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting 39
Apr 12, 2018: GamaMabs Pharma to Present New Data on Expression of Anti-Mullerian Hormone type II Receptor in Non-gynecological Cancers and on First ADC Candidate Targeting AMHRII 40
Apr 10, 2018: Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery 40
Clinical Trial Profile Snapshots 42
Appendix 979
Abbreviations 979
Definitions 979
Research Methodology 980
Secondary Research 980
About GlobalData 981
Contact Us 981
Disclaimer 981
Source 982
List of Figure
List of Figures
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2018* 19
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
GlobalData Methodology 980
List of Table
List of Tables
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2018* 8
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2018* 19
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.